Skip to main content
NIH funding notice RFA-CA-19-044

Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed)

Closed on April 25, 2019.

Posted
February 20, 2019
Close date
April 25, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,725,721 in first-year total cost, median $616,741.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 RTRB-Y (O1)]6

Most frequent institutions

  1. COLUMBIA UNIV NEW YORK MORNINGSIDE1
  2. FRED HUTCHINSON CANCER RESEARCH CENTER1
  3. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
  4. JOHNS HOPKINS UNIVERSITY1
  5. NATIONAL JEWISH HEALTH1
Competing awards under RFA-CA-19-044 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Humoral immunity after CAR-T cell therapy for B cell malignancies: The HICAR Study1U01CA247548-01HILL, JOSHUA AIDENFRED HUTCHINSON CANCER RESEARCH CENTER, WA$670,697ZCA1
2020Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome1U01CA247576-01BAI, RENYUANSTAEDTKE, VERENAJOHNS HOPKINS UNIVERSITY, MD$646,181ZCA1
2020Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy1U01AR077511-01KERN, JEFFREY ALACOUTURE, MARIOLEUNG, DONALD YMNATIONAL JEWISH HEALTH, CO$638,608ZCA1
2020Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients1U01DK124165-01COLOMBEL, JEAN-FREDERICFAITH, JEREMIAH JAMESGNJATIC, SACHAICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY$594,873ZCA1
2020Finding the optimal balance of immunotherapy efficacy and toxicity.1U01AI156189-01GERBER, DAVID ERICWAKELAND, EDWARD K.XIE, YANGUT SOUTHWESTERN MEDICAL CENTER, TX$589,033ZCA1
2020Engineering immunotherapeutic probiotics to mitigate irAE1U01CA247573-01ARPAIA, NICHOLASDANINO, TALCOLUMBIA UNIV NEW YORK MORNINGSIDE, NY$586,329ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-CA-19-044: Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed) | ScienceDex | ConductScience